Vanessa L Gates

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9159622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with ExÂVivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model. Journal of Vascular and Interventional Radiology, 2021, 32, 23-32.e1.	0.2	2
2	Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model andÂClinical Translation. Journal of Vascular and Interventional Radiology, 2021, 32, 1103-1112.e12.	0.2	11
3	Yttrium-90 Radioembolization in the VX2 Rabbit Model: Radiation Safety and Factors Influencing Delivery Efficiency. Journal of Vascular and Interventional Radiology, 2021, 32, 1569-1574.e11.	0.2	0
4	Yttrium-90 Portal Vein Radioembolization in Sprague–Dawley Rats: Dose-Dependent Imaging and Pathological Changes in Normal Liver. CardioVascular and Interventional Radiology, 2020, 43, 1925-1935.	0.9	2
5	Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model. CardioVascular and Interventional Radiology, 2020, 43, 1528-1537.	0.9	5
6	Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. Journal of Hepatology, 2020, 72, 1151-1158.	1.8	32
7	Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma. Academic Radiology, 2020, 28, 849-858.	1.3	6
8	Indicators of Lung Shunt Fraction Determined by Technetium-99Âm Macroaggregated Albumin in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1213-1222.	0.9	10
9	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor toÂtheÂLiver. Journal of Vascular and Interventional Radiology, 2017, 28, 1520-1526.	0.2	57
10	Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology, 2017, 28, 1-15.	0.2	107
11	Same-day 90Y radioembolization: implementing a new treatment paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2353-2359.	3.3	51
12	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2016, 27, 795-802.	0.2	64
13	⁹⁰ Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	2.8	79
14	Commentary on: "Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolizationâ€: European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 822-823.	3.3	1
15	Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization. Journal of Nuclear Medicine, 2015, 56, 1157-1162.	2.8	21
16	Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2038-2044.	3.3	11
17	Outpatient Single-Session Yttrium-90 Glass Microsphere Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 266-270.	0.2	53
18	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 486-493.	3.3	21

VANESSA L GATES

#	Article	IF	CITATIONS
19	Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy. Journal of Vascular and Interventional Radiology, 2014, 25, 1523-1532.e2.	0.2	55
20	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1861-1869.	3.3	80
21	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1025-1031.	0.4	43
22	Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 1056-1066.	0.2	20
23	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. Journal of Hepatology, 2013, 58, 73-80.	1.8	110
24	Positron Emission Tomography/CT after Yttrium-90 Radioembolization: Current and Future Applications. Journal of Vascular and Interventional Radiology, 2013, 24, 1153-1155.	0.2	7
25	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. Journal of Hepatology, 2013, 59, 1029-1036.	1.8	215
26	Radioembolization of Renal Cell Carcinoma Using Yttrium-90 Microspheres. Journal of Vascular and Interventional Radiology, 2013, 24, 298-300.	0.2	14
27	In Regard to Yu et al. International Journal of Radiation Oncology Biology Physics, 2013, 86, 211.	0.4	1
28	Radiation Pneumonitis Following Yttrium-90 Radioembolization: Case Report and Literature Review. Journal of Vascular and Interventional Radiology, 2012, 23, 669-674.	0.2	78
29	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.4	137
30	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.2	185
31	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	0.6	566
32	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. Gastroenterology, 2011, 141, 526-535.e2.	0.6	148
33	Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰ Y microsphere brachytherapy in the treatment of hepatic malignancies. Medical Physics, 2011, 38, 4824-4845.	1.6	208
34	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation. Journal of Hepatology, 2011, 54, 695-704.	1.8	140
35	Internal Pair Production of ⁹⁰ Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept. Journal of Nuclear Medicine, 2011, 52, 72-76.	2.8	119
36	Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology Biology Physics, 2011, 79, 163-171.	0.4	199

VANESSA L GATES

#	Article	IF	CITATIONS
37	Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization. CardioVascular and Interventional Radiology, 2010, 33, 1143-1152.	0.9	82
38	Fluoro-2-Deoxy- <scp>d</scp> -Glucose Positron Emission Tomography/Computed Tomography Predicts Extrahepatic Metastatic Potential of Colorectal Metastasis: A Practical Guide for Yttrium-90 Microsphere Liver-Directed Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 233-236.	0.7	5
39	Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology, 2009, 49, 1185-1193.	3.6	229
40	Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1494-1500.	0.4	238
41	Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. Annals of Surgical Oncology, 2009, 16, 1587-1596.	0.7	207
42	Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. Journal of Vascular and Interventional Radiology, 2009, 20, 1557-1563.	0.2	31
43	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 2008, 47, 71-81.	3.6	542
44	Radiographic Response to Yttrium-90 Radioembolization in Anterior Versus Posterior Liver Segments. CardioVascular and Interventional Radiology, 2008, 31, 1124-1132.	0.9	15
45	Unresectable Chemorefractory Liver Metastases: Radioembolization with ⁹⁰ Y Microspheres—Safety, Efficacy, and Survival. Radiology, 2008, 247, 507-515.	3.6	207
46	MR Tracking of Iron-labeled Glass Radioembolization Microspheres during Transcatheter Delivery to Rabbit VX2 Liver Tumors: Feasibility Study. Radiology, 2008, 249, 845-854.	3.6	46
47	Multimodality Imaging Following ⁹⁰ Y Radioembolization: A Comprehensive Review and Pictorial Essay. Radiographics, 2008, 28, 81-99.	1.4	128
48	Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 431-438.	0.6	157
49	Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World Journal of Gastroenterology, 2008, 14, 1664.	1.4	96
50	Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncology, 2007, 3, 73-81.	1.1	31
51	Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2007, 18, 1375-1382.	0.2	107
52	90Y Radioembolization of Metastatic Breast Cancer to the Liver: Toxicity, Imaging Response, Survival. Journal of Vascular and Interventional Radiology, 2007, 18, 621-628.	0.2	92
53	Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 305-313.	0.7	31
54	The Effect of Catheter-Directed CT Angiography on Yttrium-90 Radioembolization Treatment of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2005, 16, 1085-1091.	0.2	63

VANESSA L GATES

#	Article	IF	CITATIONS
55	90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135–150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging. Journal of Vascular and Interventional Radiology, 2005, 16, 1641-1651.	0.2	162
56	Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival. Journal of Vascular and Interventional Radiology, 2005, 16, 1627-1639.	0.2	392
57	Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging. Journal of Vascular and Interventional Radiology, 2005, 16, 1101-1106.	0.2	82
58	Angiographic Considerations in Patients Undergoing Liver-directed Therapy. Journal of Vascular and Interventional Radiology, 2005, 16, 911-935.	0.2	237
59	Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 815-820.	3.3	148
60	Relaxation in the neighborhood of a magnetic impurity in thes=1/2 Heisenberg chain at high temperatures. Physical Review B, 1994, 50, 4244-4247.	1.1	4
61	Principles of radioembolization. , 0, , 44-51.		Ο